Evidence map›Paper›PMID 30619291›Full record

ArticleFrontiers in immunology2018

β-TrCP Restricts Lipopolysaccharide (LPS)-Induced Activation of TRAF6-IKK Pathway Upstream of IκBα Signaling.

Jin Liu, Yukang Yuan, Jing Xu, Kui Xiao, Ying Xu, Tingting Guo, Liting Zhang, Jun Wang, Hui Zheng

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. SKP1-CUL1-F-box: Key molecular targets affecting disease progression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Post-translational Modifications of IκBα: The State of the Art.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jin LiuInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Yukang YuanInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Jing XuInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Kui XiaoDepartment of Respiratory Medicine, The Second Xiangya Hospital, Institute of Respiratory Disease, Central South University, Changsha, China.
Ying XuDepartment of Intensive Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Tingting GuoInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Liting ZhangInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Jun WangDepartment of Intensive Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hui ZhengInstitutes of Biology and Medical Sciences, Soochow University, Suzhou, China.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β transducin repeat-containing protein (β-TrCP) is a Skp1-Cul1-F-box ubiquitin ligase, which plays important roles in controlling numerous signaling pathways. Notably, β-TrCP induces ubiquitination and degradation of inhibitor of NF-κB (IκBα), thus triggering activation of NF-κB signaling. Here, we unexpectedly find that β-TrCP restricts TRAF6-IKK signaling upstream of IκBα induced by lipopolysaccharide (LPS). In LPS-Toll-like receptor 4 (TLR4) pathway, protein kinase D1 (PKD1) is essential for activation of TRAF6-IKK-IκBα signaling including TRAF6 ubiquitination, IKK phosphorylation and subsequent IκBα degradation. We found that LPS promotes binding of β-TrCP to PKD1, and results in downregulation of PKD1 and recovery of IκBα protein level. Knockdown of β-TrCP blocks LPS-induced downregulation of PKD1. Supplement of enough PKD1 in cells inhibits recovery of IκBα protein levels during LPS stimulation. Furthermore, we demonstrate that β-TrCP inhibits LPS-induced TRAF6 ubiquitination and IKK phosphorylation. Taken together, our findings identify β-TrCP as an important negative regulator for upstream signaling of IκBα in LPS pathway, and therefore renew the understanding of the roles of β-TrCP in regulating TLRs inflammatory signaling.

Indexed as

Animalsbeta-Transducin Repeat-Containing ProteinsGene Knockdown TechniquesHEK293 CellsHumansI-kappa B KinaseInflammationIntracellular Signaling Peptides and ProteinsLipopolysaccharidesMiceNF-KappaB Inhibitor alphaRAW 264.7 CellsSignal TransductionTNF Receptor-Associated Factor 6Ubiquitinationbeta-Transducin Repeat-Containing ProteinsBTRC protein, humanBtrc protein, mouseI-kappa B KinaseIntracellular Signaling Peptides and ProteinsLipopolysaccharidesNF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mouseTifab protein, humanTNF Receptor-Associated Factor 6TRAF6 protein, mouseE3 ligaseLPSprotein kinase D1ubiquitinationβ-TrCP

Identifiers

PMID30619291
PMCPMC6300488
OpenAlexW2904981213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.